Venn Life Sciences Grows CRO Business in Europe
Venn Life Sciences, a CRO providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the recent acquisition of two European CROs.
Venn Life Sciences, a CRO providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the recent acquisition of two European CROs. Venn acquired German CRO CRM clinical trials and Medevol Clinical Services in the UK. Venn has operations in France, Ireland, the Netherlands, Russia, the UK and a branch office in Switzerland. It also has a Clinical Resourcing business placing experienced clinical teams and individuals on projects throughout Europe.
Founded in 1996, CRM is a full-service CRO based in Rheinbach, Germany, specializing in Phases II-IV. CRM has extensive experience in dermatology, pneumology and urology, and its suite of services include initial and ongoing training for study nurses, investigators and trial teams in the areas of quality, planning andmonitoring of clinical studies.
The second acquisition is Medevol, a CRO in the UK clinical trials market since 2001, conducting full-service studies for global pharmaceutical and biotechnology companies across Phases II - IV. With extensive therapeutic experience across a broad range of indications, Medevol also provide contract staffing solutions. The company is based in Belfast.
You can read the full release here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
